Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus
Status:
Unknown status
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
It is well known that incretin, particular GLP-１enhances satiety and reduces energy intake in
controlling appetite and dietary in humans (Flint A, et al. Gutzwiller JP et al.). Recently,
incretin-based therapy has been attracted a lot of interest (Hare KJ, Knop FK). However, it
is not clear how the incretin-based therapy affects energy and content of dietary intake in
patients with type 2 diabetes mellitus (T2DM). Previously, the investigators reported the
amount of energy and content of dietary intake in type 2 diabetic Japanese patients with more
than 10 years of long time duration after discovery using questionnaire (Inoue K et al.) and
the patients were impaired a secretion of active GLP-1 (Kamoi et al).
The investigators examine whether the incretin-based therapy effects on the energy and
content of dietary intake in the same patients before and one year after administration of
incretin-related drugs using the same method previously (Inoue K et al.).